Elena Ridloff
Director/Board Member at KRONOS BIO, INC.
Net worth: 2 577 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Nello Mainolfi | M | 45 | 9 years | |
| Felix Baker | M | 55 | 7 years | |
| Ellen Chiniara | F | 65 | 5 years | |
| Michael Cloonan | M | 53 |
Sionna Therapeutics, Inc.
 Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Adam Rosenberg | M | 54 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Bruce Booth | M | 49 | 9 years | |
| Bruce Jacobs | M | 54 | 5 years | |
| Allison Frisbee | F | 41 | 4 years | |
| David Tanen | M | 52 | 7 years | |
| Tai Yin Yang | M | 70 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | 3 years |
| Arie Belldegrun | M | 74 | 7 years | |
| Joshua Kazam | M | 47 | 7 years | |
| Victor Sandor | M | 57 | 2 years | |
| Piyush Sharma | M | - | 7 years | |
| Brian Albarran | M | - | 6 years | |
| Brendan Teehan | M | 56 | 6 years | |
| Katherine Stultz | F | 50 | 1 years | |
| Elizabeth Garofalo | M | 66 | 4 years | |
| Mark Schneyer | M | 50 | 4 years | |
| Gorjan Hrustanovic | M | 35 | 4 years | |
| Roger Dansey | M | 67 | 1 years | |
| Roshawn Blunt | F | 49 | 3 years | |
| Norbert W. Bischofberger | M | 68 | 6 years | |
| Sandra Gardiner | F | 58 | 1 years | |
| Elizabeth A. Olek | M | 59 | 2 years | |
| Leigh Morgan | F | 56 | 2 years | |
| Matthew Kinsella | M | - |
Maverick Capital Ltd.
 Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | 19 years |
| Paul Clancy | M | 62 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | 5 years |
| Joanna Horobin | M | 69 | 6 years | |
| John Maraganore | M | 60 | 2 years | |
| Katherine Bishop | M | 58 | 3 years | |
| Pamela Esposito | M | 50 | 4 years | |
| Joshua Resnick | M | 49 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| Jeffrey Albers | M | 52 | 4 years | |
| Howard Marks | M | 77 |
University of Pennsylvania
| 24 years |
| Aimee Mishkin | F | - | 4 years | |
| Charles Lin | M | 39 | 5 years | |
| Sanjeev Pathak | M | - | 3 years | |
| Melissa Brody | F | - | 3 years | |
| Karen Weisbach | F | - | 3 years | |
| Juliet Williams | M | - | 3 years | |
| Rocio Martin Hoyos | F | - | 3 years | |
| Jeremy Chadwick | M | 61 | 1 years | |
| Ashwin Gollerkeri | M | - | 3 years | |
| Kevin Dushney | M | - | 3 years | |
| Raphael Amit | M | 77 |
University of Pennsylvania
| 25 years |
| Justine E. Koenigsberg | F | - | 1 years | |
| James Kihara | M | - | 4 years | |
| Vijay Sabesan | M | 51 | 3 years | |
| Ponni Subbiah | M | - | 5 years | |
| Lucian Iancovici | M | 42 |
Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc. Medical/Nursing ServicesHealth Services Sionna Therapeutics, Inc. is a clinical-stage life sciences company located in Natick, MA. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. Sionna is advancing a pipeline of small molecules engineered to correct the protein defects caused by ?F508, the most common mutation that affects the CFTR protein. The company has a first-in-class portfolio of programs directly targeting correction of ?F508-CFTR, the key and unique mechanism to enable full restoration of ?F508-CFTR function, and complementary programs targeting ICL4 and more. The CEO of the company is Michael Cloonan. | - |
| David Tykocinski | M | - |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | 13 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Leonard Bell | M | 65 | 25 years | |
| Joseph A. Madri | M | 80 | 22 years | |
| Aradhana Sarin | M | 50 | 4 years | |
| David Brennan | M | 70 | 7 years | |
| David Hallal | M | 56 | 10 years | |
| Barbara Kosacz | F | 66 | 4 years | |
| Stephen P. Squinto | M | 67 | 23 years | |
| Kory Wentworth | M | 45 | 9 years | |
| Christopher Coughlin | M | 71 | 7 years | |
| Todd Young | M | 52 | 2 years | |
| Andrew Hedin | M | 39 | 3 years | |
| Rebecka Belldegrun | M | - | - | |
| César Orosco | M | - |
University of Pennsylvania
| 6 years |
| Bill Belleville | M | - |
University of Pennsylvania
| 2 years |
| Sassan Alizadeh | M | - |
University of Pennsylvania
| 7 years |
| Sean Evan Wright | M | 50 |
University of Pennsylvania
| 2 years |
| John C. King | M | 49 | 9 years | |
| Jakob Loven | M | 46 | - | |
| Nehal Kamalapat Chopra | F | - |
University of Pennsylvania
| 4 years |
| Mark Day | M | 52 | 2 years | |
| Marianne de Backer | M | 55 | 2 years | |
| Rana Strellis | F | - | 4 years | |
| Robert Doebele | M | 53 |
University of Pennsylvania
| 4 years |
| Maja Sliwinski | F | - |
University of Pennsylvania
| 6 years |
| Karen Martin | M | - | 2 years | |
| Jonathan Keehn | M | - |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | - |
| Glenn F. Baity | M | 54 | 14 years | |
| Brian Goff | M | 55 | 4 years | |
| James S. Riepe | M | - |
University of Pennsylvania
| 4 years |
| Francois Nader | M | 67 | 4 years | |
| Anne-Marie Law | F | 56 | 3 years | |
| Rockford Norby | M | 89 | 18 years | |
| John Martin | M | 72 | - | |
| M. Burns | F | 66 | 4 years | |
| Michael Weiser | M | 61 |
Paramount BioCapital Asset Management, Inc.
 Paramount BioCapital Asset Management, Inc. Investment ManagersFinance Founded in 1991 by Dr. Lindsay Rosenwald, Paramount BioCapital Asset Management, Inc. is a hedge fund manager located in New York City. The firm is a subsidiary of Paramount BioCapital, Inc. | 7 years |
| Mehul Trivedi | M | 53 |
University of Pennsylvania
| 9 years |
| Paul Friedman | M | 81 | 4 years | |
| Erika G. Long | F | - |
Maverick Capital Ltd.
Maverick Capital Ltd. Investment ManagersFinance Maverick Capital Ltd. (Maverick) is a SEC-registered investment advisor and hedge fund manager headquartered in Dallas, Texas. They are a wholly-owned subsidiary of Cohasset Ltd. The firm was founded by Lee Ainslie III in 1993. Maverick provides advisory services to hedge funds, funds of funds, funds making venture capital investments, a private equity fund and related co-investment vehicle, other pooled investment vehicles, and institutional investors. | - |
| Yasir Al-Wakeel | M | 42 | 3 years | |
| Saam Farhang | M | - |
University of Pennsylvania
| 5 years |
| Taran Sang Yong Bae | M | - |
University of Pennsylvania
| 2 years |
| Otello Stampacchia | M | 55 | 5 years | |
| William Keller | M | 75 | 6 years | |
| Jack Mollen | M | 73 | 7 years | |
| Austin Kim | M | 60 | 6 years | |
| Larry L. Mathis | M | 80 | 10 years | |
| Ludwig Hantson | M | 61 | 4 years | |
| Marni Kottle | F | - | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Elena Ridloff
- Personal Network
